Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 21, Pages 17288-17296Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M111.300483
Keywords
-
Categories
Funding
- National Institutes of Health [R01-AG026660]
- American Health Assistance Foundation
- Alzheimer Association
- Institutional Training Grant [T32 GM073546-01A19, T32 GM073546-04]
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
- William Randolph Hearst Fund in Experimental Therapeutics
Ask authors/readers for more resources
Presenilin-1 (PS1) is the catalytic subunit of gamma-secretase, and mutations in this protein cause familial Alzheimer Disease (FAD). However, little is known about how these mutations affect the active site of gamma-secretase. Here, we show that PS1 mutations alter the S2 subsite within the active site of gamma-secretase using a multiple photoaffinity probe approach called photophore walking. Moreover, we developed a unique in vitro assay with a biotinylated recombinant Notch1 substrate and demonstrated that PS1 FAD mutations directly and significantly reduced gamma-secretase activity for Notch1 cleavage. Substitution of the Notch Cys-1752 residue, which interacts with the S2 subsite, with Val, Met, or Ile has little effect on wild-type PS1 but leads to more efficient substrates for mutant PS1s. This study indicates that alteration of this S2 subsite plays an important role in determining the activity and specificity of gamma-secretase for APP and Notch1 processing, which provides structural basis and insights on how certain PS1 FAD mutations lead to AD pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available